Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human induced-T-to-natural killer cells have potent anti-tumour activities.
Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P, Zhang Z, Li P. Jiang Z, et al. Among authors: feng w. Biomark Res. 2022 Mar 24;10(1):13. doi: 10.1186/s40364-022-00358-4. Biomark Res. 2022. PMID: 35331335 Free PMC article.
Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.
Nie Y, Feng F, Luo W, Sanders AJ, Zhang Y, Liang J, Chen C, Feng W, Gu W, Liao W, Wang W, Chen J, Zhang L, Jiang WG, Li J. Nie Y, et al. Among authors: feng w, feng f. Cancer Gene Ther. 2022 Oct;29(10):1405-1417. doi: 10.1038/s41417-022-00459-0. Epub 2022 Mar 30. Cancer Gene Ther. 2022. PMID: 35354949 Free PMC article. Retracted.
Retraction Note: Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.
Nie Y, Feng F, Luo W, Sanders AJ, Zhang Y, Liang J, Chen C, Feng W, Gu W, Liao W, Wang W, Chen J, Zhang L, Jiang WG, Li J. Nie Y, et al. Among authors: feng w, feng f. Cancer Gene Ther. 2023 Nov;30(11):1583. doi: 10.1038/s41417-023-00677-0. Cancer Gene Ther. 2023. PMID: 37833404 Free PMC article. No abstract available.
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Hao Y, Chen J, Zhang G, Qu S, Li Y, Feng W, Yang M, Liu B, Ouyang W, Liang J, Yu Z, Kang X, Xue S, Yang G, Yan W, Yang Y, Liu Z, Peng Y, Fanslow B, Huang X, Zhang L, Zhao H. Zhao Y, et al. Among authors: feng w. J Hematol Oncol. 2023 May 8;16(1):50. doi: 10.1186/s13045-023-01445-1. J Hematol Oncol. 2023. PMID: 37158938 Free PMC article. Clinical Trial.
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Huang X, Liu Q, Zhong G, Peng Y, Liu Y, Liang L, Hong H, Feng W, Yang S, Zhang Y, Xian S, Li Z, Zhou Y, Zhang Z, Jiang W, Liang J, Liu ZG. Huang X, et al. Among authors: feng w. J Exp Clin Cancer Res. 2022 Oct 12;41(1):300. doi: 10.1186/s13046-022-02510-2. J Exp Clin Cancer Res. 2022. PMID: 36224603 Free PMC article. Clinical Trial.
6,491 results